Hydrochloorthiazide Ratiopharm

Hydrochloorthiazide Ratiopharm is an oral tablet containing the thiazide diuretic hydrochlorothiazide. Marketed in the European Union, the product does not specify a particular strength or dosage form beyond the standard tablet presentation. It is a prescription‑only medication used to manage fluid balance and blood pressure under medical supervision. It belongs to the class of antihypertensive agents and is intended for patients diagnosed with hypertension or edema, following a physician’s assessment.

Hydrochloorthiazide Ratiopharm is prescribed primarily for conditions where reduction of excess fluid or lowering of elevated blood pressure is required. The medication is part of a broader therapeutic plan that may include lifestyle changes and other antihypertensive agents.

- Hypertension (high blood pressure) management, often as first‑line or adjunct therapy. - Edema associated with congestive heart failure, liver cirrhosis, or renal disease. - Prevention of fluid overload in patients undergoing certain surgical procedures. - Combination therapy with other diuretics or antihypertensives to achieve target blood pressure. - Short‑term control of hypertension in patients intolerant to other drug classes.

Like all diuretics, Hydrochloorthiazide Ratiopharm may cause a range of adverse reactions, varying from mild to severe.

Common: - Increased urination and mild thirst. - Electrolyte disturbances such as low potassium or sodium. - Dizziness or light‑headedness, especially when standing. - Elevated blood glucose levels in susceptible individuals.

Serious: - Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia). - Acute kidney injury or worsening renal function. - Allergic reactions including rash, angioedema, or anaphylaxis.

Healthcare providers should evaluate several factors before initiating Hydrochloorthiazide Ratiopharm to ensure safe and effective use.

- Assess renal function; avoid use in severe impairment. - Monitor serum electrolytes, especially potassium and sodium, during therapy. - Use cautiously in patients with diabetes or gout, as uric acid levels may rise. - Consider pregnancy status; the drug is generally avoided unless benefits outweigh risks. - Review concomitant medications that may potentiate hypotension or electrolyte loss. - Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness. - Encourage adequate fluid and dietary potassium intake unless contraindicated.

Hydrochloorthiazide Ratiopharm can interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Other thiazide or loop diuretics, which may cause excessive fluid and electrolyte loss. - Lithium, as thiazides can increase lithium concentrations and toxicity risk. - NSAIDs (e.g., ibuprofen, naproxen) that may reduce diuretic effectiveness and impair renal function.

Use with caution: - ACE inhibitors, ARBs, or beta‑blockers, which together may enhance blood pressure lowering. - Antidiabetic agents, because thiazides can raise blood glucose. - Anticoagulants (e.g., warfarin), as electrolyte shifts may affect coagulation parameters.